Aberdeen Group plc Takes $6.16 Million Position in Kiniksa Pharmaceuticals International, plc $KNSA

Aberdeen Group plc purchased a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the third quarter, Holdings Channel.com reports. The fund purchased 158,722 shares of the company’s stock, valued at approximately $6,163,000.

Several other institutional investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC increased its position in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth $31,000. USA Financial Formulas purchased a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter worth about $32,000. Quantbot Technologies LP purchased a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter worth about $43,000. Finally, Farther Finance Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 582.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock valued at $53,000 after acquiring an additional 1,159 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.56, for a total transaction of $500,714.88. Following the completion of the sale, the chief operating officer directly owned 16,666 shares in the company, valued at $692,638.96. The trade was a 41.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Mark Ragosa sold 17,845 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the completion of the transaction, the chief financial officer directly owned 12,086 shares of the company’s stock, valued at approximately $523,082.08. This represents a 59.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 123,823 shares of company stock valued at $5,244,967 over the last three months. 53.48% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals International Trading Up 1.3%

Shares of KNSA opened at $47.77 on Friday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $18.25 and a 12-month high of $47.86. The company has a market cap of $3.62 billion, a PE ratio of 106.16 and a beta of 0.06. The stock has a 50-day moving average price of $42.72 and a 200-day moving average price of $39.37.

Analyst Ratings Changes

Several equities analysts have recently weighed in on KNSA shares. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Canaccord Genuity Group began coverage on Kiniksa Pharmaceuticals International in a research report on Thursday. They set a “buy” rating and a $62.00 target price on the stock. Finally, Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.71.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.